Edition:
United States

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

41.78USD
2:22pm EST
Change (% chg)

$1.26 (+3.11%)
Prev Close
$40.52
Open
$40.57
Day's High
$41.93
Day's Low
$40.55
Volume
1,148,851
Avg. Vol
2,127,956
52-wk High
$45.86
52-wk Low
$29.44

Select another date:

Thu, Dec 14 2017

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents

* MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS

BRIEF-Mylan Says Teva Has Dismissed Its Pending Litigation Against Co

* MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN

BRIEF-Mylan And Aspen Announce Launch Of Generic Busulfex Injection

* MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION

FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.

UPDATE 3-FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

* Approval ups confidence in Mylan's biosimilar efforts -analysts

BRIEF-FDA Approves Mylan's Heparin Sodium Injection

* FDA APPROVAL OF HEPARIN SODIUM INJECTION CONTINUES TO DEMONSTRATE MYLAN'S DEEP EXPERTISE IN DEVELOPING COMPLEX PRODUCTS

FDA approves Mylan's biosimilar of Roche's breast cancer treatment

Dec 1 The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster breast cancer treatment Herceptin.

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

BRIEF-Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)

* Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)

Select another date: